Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Androclus Therapeutics
Immune responses to hsp60 epitopes in juvenile idiopathic arthritis published
August 10th, 2005
Androclus Therapeutics announced publication in the Lancet of immunoscreening results of heat-shock protein 60 (hsp60) derived peptides in patients with juvenile idiopathic arthritis (JIA). Researchers from University of Utrecht, University of California, San Diego, La Jolla Institute for Allergy and Immunology, and Androclus Therapeutics demonstrated that peptides derived from hsp60 could represent novel treatment options to specifically modulate the immune system of patients with JIA. The technology was developed in professor Albani's laboratory at the University of California, San Diego and has been licensed to Androclus Therapeutics. JIA...
Source: Biotech Week (2005-08-10)
|
